The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Abstract
MDM2 binds the p53 tumor suppressor protein with high affinity and negatively modulates its transcriptional activity and stability. Overexpression of MDM2, found in many human tumors, effectively impairs p53 function. Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy. Here, we identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes. These compounds bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“WB138 increases the levels of both p53 and MDM2, which is consistent with the activity of previous reports on MDM2 inhibitors[28,32–36].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [32]
In the citing paper
“Nutlin-3a had the strongest activity, and its binding activity with MDM2 reached 90 nM.”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [20]
In the citing paper
“At 200 mg/kg, twice a day, 20 days after oral administration of Nutlin-3a, the tumor growth inhibition rate reached 90%, with no obvious side effects [20].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [20]
In the citing paper
“Moreover, others have shown that inhibition of MDM2 binding to p53 or p73α appears to be more effective at promoting p53- and p73α-mediated apoptosis in cancer cells compared with normal cells.19,45”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [45]
In the citing paper
“Nutlin-3a is a small molecule, which binds to the N-terminal hydrophobic pocket of Mdm2 and blocks protein-protein interactions (PPIs) between Mdm2 and p53 (10).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [10]
In the citing paper
“It has been reported that a consequence of Nutlin treatment is elevated Mdm2 protein levels, and this occurs in cells with or without p53 (6,8).”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [6]
In the citing paper
“Nutlin-3 is a small molecule inhibitor of Mdm2/p53 interaction that can induce apoptosis in cancer cells through activation of p53.”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [6]
In the citing paper
“Nonmalignant tissues tolerate inhibition of Mdm2, and no overt toxicity was observed in preclinical in vivo models.9,11”
From Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death (2013) · cites this paper as [9]
In the citing paper
“For example, small molecule antagonism of the Mdm2–p53 interaction promotes p53-dependent tumor regression in murine models [102,103].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [103]
In the citing paper
“Small-molecule PPI antagonists that disrupt the p53–MDM2 interaction have been identified, including nutlin 3a96 and MI-219 (Ref. 97).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [96]
In the citing paper
“To utilize MDM2 for the PROTAC system, the discovery of nutlins, small molecules that bind MDM2 at the p53 interaction interface, was a crucial step [66].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [66]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Flagged first, then by citations
Research works printed but not linked: 3
- D. Freedman, A. J. Levine, Cell. Mol. Life Sci.5, 96 (1999).
- R. Zhang, H. Wang, Methods Mol. Med.85, 205 (2003).
- L. T. Vassilevet al., Anticancer Drug Des.13, 359 (2001).
Cited by
Sorted by citations
Items 801–900 of 1,103
Huber, W. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.744 · Cited by 104
Wang, S., & El‐Deiry, W. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1734 · Cited by 104
α-Helix Mimicry with α/β-Peptides
Johnson, L. M., & Gellman, S. H. (2013) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-394292-0.00019-9 · Cited by 103
Mulay, S. R., Thomasová, D., Ryu, M., & Anders, H. (2012) · Kidney International · doi:10.1038/ki.2011.482 · Cited by 104
Das, M., & Sahoo, S. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032920 · Cited by 103
Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo
Phesse, T. J., Myant, K., Cole, A. M., Ridgway, R. A., Pearson, H. B., Muncan, V., BRINK, G. R. V. D., Vousden, K. H., Sears, R. C., Vassilev, L. T., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.15 · Cited by 102
Self-citationEnabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
Koes, D. R., Khoury, K., Huang, Y., Wang, W., Biśta, M., Popowicz, G. M., Wolf, S., Holak, T. A., Dömling, A. S. S., & Camacho, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032839 · Cited by 105
Vita, A. D., Mercatali, L., Recine, F., Pieri, F., Riva, N., Bongiovanni, A., Liverani, C., Spadazzi, C., Miserocchi, G., Amadori, D., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s112580 · Cited by 103
Zeng, K., Chen, X., Hu, X., Liu, X., Xu, T., Sun, H., Pan, Y., He, B., & Wang, S. (2018) · Oncogene · doi:10.1038/s41388-018-0352-7 · Cited by 101
Khurana, A., & Shafer, D. A. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s172315 · Cited by 111
Murase, D., Hachiya, A., Amano, Y., Ohuchi, A., Kitahara, T., & Takema, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805570200 · Cited by 106
Cell-based high-content screening of small-molecule libraries
Korn, K., & Krausz, E. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.08.030 · Cited by 104
Targeting Ubiquitination for Cancer Therapies
Morrow, J. K., Lin, H., Sun, S., & Zhang, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.148 · Cited by 102
Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway
Busso, C. S., Iwakuma, T., & Izumi, T. (2009) · Oncogene · doi:10.1038/onc.2009.5 · Cited by 100
Clickable Protein Nanocapsules for Targeted Delivery of Recombinant p53 Protein
Zhao, M., Liu, Y., Hsieh, R. S., Wang, N., Tai, W., Joo, K., Wang, P., Gu, Z., & Tang, Y. (2014) · Journal of the American Chemical Society · doi:10.1021/ja508083g · Cited by 103
Making Sense of Intrinsically Disordered Proteins
Dyson, H. J. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.01.030 · Cited by 101
C16-ceramide is a natural regulatory ligand of p53 in cellular stress response
Fekry, B., Jeffries, K. A., Esmaeilniakooshkghazi, A., Szulc, Z. M., Knagge, K. J., Kirchner, D. R., Horita, D. A., Krupenko, S. A., & Krupenko, N. I. (2018) · Nature Communications · doi:10.1038/s41467-018-06650-y · Cited by 103
p53, a novel regulator of lipid metabolism pathways
Goldstein, I., Ezra, O., Rivlin, N., Molchadsky, A., Madar, S., Goldfinger, N., & Rotter, V. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.022 · Cited by 102
Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., & Stockwell, B. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0104 · Cited by 100
Cullin E3 Ligases and Their Rewiring by Viral Factors
Mahon, C., Krogan, N., Craik, C., & Pick, E. (2014) · Biomolecules · doi:10.3390/biom4040897 · Cited by 101
Haase, H. S., Peterson‐Kaufman, K. J., Levengood, S. K. L., Checco, J. W., Murphy, W. L., & Gellman, S. H. (2012) · Journal of the American Chemical Society · doi:10.1021/ja302469a · Cited by 101
Miyachi, M., Kakazu, N., Yagyu, S., Katsumi, Y., Tsubai-Shimizu, S., Kikuchi, K., Tsuchiya, K., Iehara, T., & Hosoi, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2955 · Cited by 101
Motif mediated protein-protein interactions as drug targets
Corbi‐Verge, C., & Kim, P. M. (2016) · Cell Communication and Signaling · doi:10.1186/s12964-016-0131-4 · Cited by 106
Targeting FROUNT with Disulfiram Regulates Macrophage Responses in Cancer
Terashima, Y., Toda, E., Itakura, M., Otsuji, M., Yoshinaga, S., Okumura, K., Shand, F. H. W., Komohara, Y., Takeda, M., Kokubo, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-020-14338-5 · Cited by 104
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Wang, S., & Chen, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 104
Technology platforms for pharmacogenomic diagnostic assays
Koch, W. H. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1496 · Cited by 101
Jain, A. K., Allton, K. L., Duncan, A. D., & Barton, M. C. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01705-12 · Cited by 103
NHERF1/EBP50 Head-to-Tail Intramolecular Interaction Masks Association with PDZ Domain Ligands
Morales, F. C., Takahashi, Y. K., Momin, S., Adams, H. P., Chen, X., & Georgescu, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01372-06 · Cited by 97
MdmX is a substrate for the deubiquitinating enzyme USP2a
Allende-Vega, N., Sparks, A., Lane, D. P., & Saville, M. K. (2010) · Oncogene · doi:10.1038/onc.2009.330 · Cited by 100
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
Kato, S., Yoshino, T., Shibasaki, M., Kanai, M., & Matsunaga, S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203005 · Cited by 100
A limited number of double-strand DNA breaks is sufficient to delay cell cycle progression
van den Berg, J., Manjón, A. G., Kielbassa-Elkadi, K., Feringa, F. M., Freire, R., & Medema, R. H. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky786 · Cited by 101
Henchey, L. K., Porter, J. R., Ghosh, I., & Arora, P. S. (2010) · ChemBioChem · doi:10.1002/cbic.201000378 · Cited by 104
Ray, R. M., Bhattacharya, S., & Johnson, L. R. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0538-0 · Cited by 100
Leu, J. I.-J., & George, D. L. (2007) · Genes & Development · doi:10.1101/gad.1567107 · Cited by 102
van der Deen, M., Taipaleenmäki, H., Zhang, Y., Teplyuk, N. M., Gupta, A., Cinghu, S., Shogren, K. L., Maran, A., Yaszemski, M. J., Ling, L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445890 · Cited by 100
Boudreau, H. E., Casterline, B. W., Burke, D. J., & Leto, T. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.165 · Cited by 102
Preeclampsia Is Associated with Alterations in the p53-Pathway in Villous Trophoblast
Sharp, A. N., Heazell, A. E. P., Baczyk, D., Dunk, C., Lacey, H. A., Jones, C. J. P., Perkins, J., Kingdom, J. C., Baker, P. N., & Crocker, I. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087621 · Cited by 98
Emerging drugs for high-grade osteosarcoma
Hattinger, C. M., Pasello, M., Ferrari, S., Picci, P., & Serra, M. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.505603 · Cited by 99
Estrada‐Ortiz, N., Neochoritis, C. G., & Dömling, A. S. S. (2015) · ChemMedChem · doi:10.1002/cmdc.201500487 · Cited by 101
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
Herrero, A. B., Rojas, E. A., Misiewicz-Krzemińska, I., Krzemiński, P., & Gutierrez, N. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122003 · Cited by 102
Synthesis of new thiazolo-pyrrolidine–(spirooxindole) tethered to 3-acylindole as anticancer agents
Islam, M. S., Ghawas, H. M., El‐Senduny, F. F., Al‐Majid, A. M., Elshaier, Y. A. M. M., Badria, F. A.-E., & Barakat, A. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.036 · Cited by 99
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy
Nakamura, M., Obata, T., Daikoku, T., & Fujiwara, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215482 · Cited by 101
Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy
Aliabadi, F., Sohrabi, B., Mostafavi, E., Pazoki–Toroudi, H., & Webster, T. J. (2021) · Open Biology · doi:10.1098/rsob.200390 · Cited by 101
F-box protein interactions with the hallmark pathways in cancer
Randle, S. J., & Laman, H. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.013 · Cited by 100
Laptenko, O., Beckerman, R., Freulich, E., & Prives, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105680108 · Cited by 102
Overcoming limitations of natural anticancer drugs by combining with artificial agents
Blagosklonny, M. V. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.002 · Cited by 99
Targeting and tinkering with interaction networks
Russell, R. B., & Aloy, P. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.119 · Cited by 99
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 101
The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models
Wang, W., Qin, J., Voruganti, S., Srivenugopal, K. S., Nag, S. A., Patil, S. A., Sharma, H., Wang, M., Wang, H., Buolamwini, J. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms6086 · Cited by 100
Peltonen, K., Colis, L. C., Liu, H., Jäämaa, S., Moore, H. M., Enbäck, J., Laakkonen, P., Vaahtokari, A., Jones, R. J., af Hällström, T. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012996 · Cited by 107
Transcriptional regulation of cellular senescence
Lanigan, F., Geraghty, J. G., & Bracken, A. P. (2011) · Oncogene · doi:10.1038/onc.2011.34 · Cited by 95
Disrupting the Scaffold to Improve Focal Adhesion Kinase–Targeted Cancer Therapeutics
Cance, W. G., Kurenova, E., Marlowe, T. A., & Golubovskaya, V. (2013) · Science Signaling · doi:10.1126/scisignal.2004021 · Cited by 98
Ojida, A., Inoue, M.-A., Mito-oka, Y., Tsutsumi, H., Sada, K., & Hamachi, I. (2006) · Journal of the American Chemical Society · doi:10.1021/ja056585k · Cited by 97
Donati, G., Bertoni, S., Brighenti, E., Vici, M., Treré, D., Volarević, S., Montanaro, L., & Derenzini, M. (2011) · Oncogene · doi:10.1038/onc.2011.48 · Cited by 100
Watanabe, M., Moon, K. D., Vacchio, M. S., Hathcock, K. S., & Hodes, R. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.006 · Cited by 101
Edelmann, M. J., Nicholson, B., & Kessler, B. M. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002031 · Cited by 97
Scheffner, M., & Staub, O. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s6 · Cited by 99
Koster, R., Timmer‐Bosscha, H., Bischoff, R., Gietema, J. A., & de Jong, S. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.33 · Cited by 100
The social network of a cell: Recent advances in interactome mapping
Charbonnier, S., Gallego, O., & Gavin, A. (2008) · Biotechnology annual review · doi:10.1016/s1387-2656(08)00001-x · Cited by 100
Chang, L., Miyata, Y., Ung, P. M. U., Bertelsen, E. B., McQuade, T. J., Carlson, H. A., Zuiderweg, E. R. P., & Gestwicki, J. E. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.010 · Cited by 100
S100A4 interacts with p53 in the nucleus and promotes p53 degradation
Orre, L. M., Panizza, E., Kaminskyy, V. O., Vernet, E., Gräslund, T., Zhivotovsky, B., & Lehtiö, J. (2013) · Oncogene · doi:10.1038/onc.2013.213 · Cited by 102
Targeting the p53 Pathway in Retinoblastoma with Subconjunctival Nutlin-3a
Brennan, R. C., Federico, S. M., Bradley, C. L., Zhang, J., Flores‐Otero, J., Wilson, M. W., Stewart, C. F., Zhu, F., Guy, K., & Dyer, M. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0058 · Cited by 97
Potu, H., Sgorbissa, A., & Brancolini, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1942 · Cited by 99
Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo
Lee, M. K., Teoh, W. W., Phang, B. H., Tong, W., Wang, Z. Q., & Sabapathy, K. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.022 · Cited by 104
The Ubiquitin-Proteasome System Meets Angiogenesis
Rahimi, N. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0555 · Cited by 102
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Jiang, M., Pabla, N., Murphy, R. F., Yang, T., Yin, X.-M., Degenhardt, K., White, E., & Dong, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606928200 · Cited by 97
Met acts on Mdm2 via mTOR to signal cell survival during development
Moumen, A., Patané, S., Porras, A., Dono, R., & Maina, F. (2007) · Development · doi:10.1242/dev.02820 · Cited by 95
Anil, B., Riedinger, C., Endicott, J., & Noble, M. E. M. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913004459 · Cited by 95
Selective and Potent Proteomimetic Inhibitors of Intracellular Protein–Protein Interactions
Barnard, A., Long, K., Martin, H. L., Miles, J. A., Edwards, T. A., Tomlinson, D. C., Macdonald, A., & Wilson, A. J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410810 · Cited by 98
Schupp, M., Chen, F., Briggs, E. R., Rao, S. J., Pelzmann, H. J., Pessentheiner, A. R., Bogner‐Strauß, J. G., Lazar, M. A., Baldwin, D. A., & Prokesch, A. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-758 · Cited by 103
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103
The ubiquitin–proteasome system and its potential application in hepatocellular carcinoma therapy
Chen, Y., Wu, H., & Shen, X. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.023 · Cited by 99
Regulation of the p14ARF-Mdm2-p53 pathway: An overview in breast cancer
Agrawal, A., Yang, J., Murphy, R. F., & Agrawal, D. K. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2006.07.001 · Cited by 95
Saddler, C. M., Ouillette, P. D., Kujawski, L. A., Shangary, S. K., Talpaz, M., Kaminski, M. S., Erba, H. P., Shedden, K., Wang, S., & Malek, S. N. (2007) · Blood · doi:10.1182/blood-2007-09-112698 · Cited by 96
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro
Krajewski, M., Ozdowy, P., D’Silva, L., Rothweiler, U., & Holak, T. A. (2005) · Nature Medicine · doi:10.1038/nm1105-1135 · Cited by 96
Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition
Wang, Z., Zheng, M., Li, Z. F., Li, R., Jia, L., Xiong, X., Southall, N. T., Wang, S., Xia, M., Austin, C. P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0891 · Cited by 97
Drakos, E., Thomaides, A. X., Medeiros, L. J., Jiang, L., Leventaki, V., Konopleva, M. Y., Andreeff, M., & Rassidakis, G. Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2581 · Cited by 98
p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53
Chen, L., Yin, H. H., Farooqi, B., Sebti, S. M., Hamilton, A. D., & Chen, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0342 · Cited by 97
Unleashing the power of p53: lessons from mice and men: Figure 1.Preprint
Poyurovsky, M. V., & Prives, C. L. (2006) · Genes & Development · doi:10.1101/gad.1397506 · Cited by 96
Differential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage
Pereg, Y., Lam, S., Teunisse, A., Biton, S., Meulmeester, E., Mittelman, L., Buscemi, G., Okamoto, K., Taya, Y., Shiloh, Y., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00562-06 · Cited by 93
Gene amplification: mechanisms and involvement in cancer
Matsui, A., Ihara, T., Suda, H., Mikami, H., & Semba, K. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0026 · Cited by 103
The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
Johnson, D. E. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0005 · Cited by 97
p53-Independent Effects of Mdm2
Bohlman, S., & Manfredi, J. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_13 · Cited by 98
Wang, S., Jiang, Y., Wu, S., Dong, G., Miao, Z., Zhang, W., & Sheng, C. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b00155 · Cited by 95
Regulation of Programmed Cell Death by the P53 Pathway
Kuribayashi, K., & El‐Deiry, W. S. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_10 · Cited by 95
Natural product-like chemical space: search for chemical dissectors of macromolecular interactions
Reayi, A., & Arya, P. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.04.007 · Cited by 95
Cox, M. L., & Meek, D. W. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.11.014 · Cited by 95
Gu, Y., Zhang, T., Qiu, X., Zhang, X., Gan, X., Fang, Y., Xu, X., & Xu, R. (2009) · Toxicology · doi:10.1016/j.tox.2009.11.013 · Cited by 95
p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?
Levesque, A. A., & Eastman, A. R. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl214 · Cited by 95
Mdm2 facilitates the association of p53 with the proteasome
Kulikov, R., Letienne, J., Kaur, M., Grossman, S. R., Arts, J., & Blattner, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911716107 · Cited by 94
Proteasome-associated deubiquitinases and cancer
Mofers, A., Pellegrini, P., Linder, S. T., & D’Arcy, P. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9697-6 · Cited by 101
Li, X., Yao, Z., Yang, D., Jiang, X., Sun, J., Tian, L., Hu, J., Wu, B., & Bai, W. (2019) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2019.121706 · Cited by 94
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Zhu, J., Zhou, L., Wu, G., Koenig, H., Lin, X., Li, G., Qiu, X., Chen, C., Hu, C., Goldblatt, E. M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201760 · Cited by 99
Gupta, A., Bharadwaj, M., Kumar, A., & Mehrotra, R. (2016) · Topics in Current Chemistry · doi:10.1007/s41061-016-0089-0 · Cited by 95
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
Roh, J., Kang, S. K., Minn, I., Califano, J. A., Sidransky, D., & Koch, W. M. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.10.011 · Cited by 92
Natural Compounds: Leads or Ideas? Bioinspired Molecules for Drug Discovery
Beghyn, T. B., Deprez-Poulain, R. F., Willand, N., Folléas, B., & Deprez, B. P. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00673.x · Cited by 95
Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction
Hardcastle, I. R., Ahmed, S. U., Atkins, H., Calvert, H., Curtin, N. J., Farnie, G., Golding, B. T., Griffin, R. J., Guyenne, S., Hutton, C., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.061 · Cited by 94
Chlamydia infection depends on a functional MDM2-p53 axis
González, E., Rother, M., Kerr, M. C., Al‐Zeer, M. A., Lubad, M. A., Kessler, M., Brinkmann, V., Loewer, A., & Meyer, T. F. (2014) · Nature Communications · doi:10.1038/ncomms6201 · Cited by 93
Metadata
- Authors
- Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., & Liu, E. A.
- Affiliations
- Department of Discovery Oncology, Roche Research Center, Hoffmann–La Roche, Inc., Nutley, NJ 07110, USA.
- Corresponding author
- Vassilev, Lyubomir T.
- Venue
- Science
- Published
- 2004-02-06
- Volume
- 303
- Issue
- 5659
- Pages
- 844-848
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2097933346
- Cited by
- 4,661
- References
- 21
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 169 · 2023: 203 · 2022: 204 · 2021: 199 · 2020: 226 · 2019: 212 · 2018: 216 · 2017: 209 · 2016: 258 · 2015: 248 · 2014: 296 · 2013: 273 · 2012: 265
- FWCI
- 83.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, p53, small molecule antagonists, p53 stabilization, p53-MDM2 interaction, cancer therapy, cell cycle arrest, apoptosis, tumor xenografts, crystal structure
- MeSH terms
- Animals, Binding Sites, Cell Cycle, Cell Division, Cell Line, Cell Survival, Crystallization, Dose-Response Relationship, Drug, Humans, Imidazoles, Mice, Nude, Models, Molecular, Molecular Weight, Neoplasm Transplantation, Neoplasms, Experimental, Nuclear Proteins, Phosphorylation, Piperazines, Protein Conformation, Proto-Oncogene Proteins, Stereoisomerism, Transplantation, Heterologous, Gene Expression, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Crystallography, X-Ray, NIH 3T3 Cells, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21, Mice, Proto-Oncogene Proteins c-mdm2, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
